Children with idiopathic congenital growth hormone deficiency (ICGHD) frequently have a history of significant perinatal complications. We have investigated the hypothesis that children with perinatal complications represent a discreet etiologic subset of children with ICGHD characterized by abnormalities of prolactin secretion. Thirty-two children with newly diagnosed ICGHD were studied by measuring the prolactin response to TRH. Fifteen normal children were studied as controls. Children were classified as ICGHD on the basis of documented growth hormone deficiency, growth records compatible with a congenital onset and absence of findings suggesting an acquired or definable lesion. Sixteen of the ICGHD children had a history of significant complications dur ing the perinatal period. Mean baseline prolactin in this group was 22.0f4.2 ng/ml (MeanCSEM). This was significantly greater than the baseline prolactin in children with ICGHD and normal perinatal histories (11.4 + 1.7 nglml) and normal children (8.7 + 1.6 ng/ml, p < .03, Student's t-test). There was no significant difference in peak prolactin concentration 15 minutes after TRH injection in the three groups (51.7f 7.3, 52.lf 7.8 and 45.8f 4.7 ng/ml, p >.05). We conclude that hypothalamic compromise associated with perinatal complications is the etiology of growth hormone deficiency in a subset of children with ICGHD. Vigorous follow-up of at-risk children is recommended. Thyroid hormones enhance fetal lung maturation; this effect is synergistic with that of glucocorticoids. Their potential clinical usefulness for the prevention of RDS is limited by poor transplacental passage, TRH has been reported to cross the placenta and to stimulate the fetal pituitary-thyroid axis, In order to evaluate its effectiveness pregnant women at term were injected with either saline (n=3), TRH (~hypinone, Abbot) 400 pg (n=4), or TRH 600 pg (n=3), 2 h prior to elective cesarean section. Serum levels of TSH, T3 and prolactin were determined by RIA in mothers and neonates. Administration of 400 pg TRH resulted in a 275% increase in maternal TSH levels and a 22% and 75% increase in T3 and prolactin levels, resp. 600 pg of TRH produced a 309% increase in maternal TSH, but no further increase in Tj or prolactin. The cord blood levels in the babies were as follows: TSH T3 Prolact in Controls:
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3.2 punits/ml 66 ng/dl 219 ng/ml TRH, 400 pg: 25 punits/ml 149 ng/dl 309 ng/ml All neonates exhibited the normal postnatal surge in T3 and prolactin levels, No side effects were noted in the mothers or infants. Maternal administration of TRH results in a large increase in fetal T3 levels. TRH could potentially be used to accelerate fetal lung maturation in humans. concentration was high, (40nglml) but much lower than his "usual therapeutic levels which varied between 300 and 600ng/ml. The patient and his parents denied any lack of cmpliance. We tested whether low doses of ethinyl estradiol (EE) would stimulate GH independently of SM-C inhibition, after we found EE 2 50 mcg/m Id x 2d to augment peak GH responses to L-dopa testing (LDT) while lowering SM (Rich et al, Pediatr.Res. 13:329A,1979) .
DIFFERENTIAL MEASUREMENT OF VITAMIN D AND D

M E T~L I T E S : ASSESSMENT OF COMPLIANCE WITH $ITAMIN D~
ESTROGEN AT LOW DOSES RAPIDLY AUCXENTS GROWTH HORMONE (GH) RELEASE INDEPENDENTLY OF SOMATOMEDIN-C (SM-C).
We2first examined the effect of one bedtime dose EE(29+2(SP1) mcglm ) upon GF$ reserve in 8 prepubertal short-normal chTldren.
L-dopa(0.3 gmlm ) stimulated GH to 1 7 nglml inconsistently (618) before EE. EE resulted in a significant increase $n peak GH response (295 ng/ml)(p<.05) to LDT. EE (10-30mcglm ) was then given for 2 days prior to repeat LDT in 15 prepubertal children with the following results.
EE (mcg/mL/d) n PEAK GH RESPONSE (nglml) Before EE Rx 15 13.9 2 2.3 12 + 2 3 13.7 + 6.7
27 z 1 12 35.4 3.8 (p<.Ol) GH responses to LDT were <7 ng/ml in 3/15 prior to EE but were consistently 27 ng/m$ after EE. Augmentation of the GH response by EE at 2 7 5 pcg/m /d was of similar magnitude to that noted with 50 mcg/m /d EE, but this low-dose EE did not act via lowering SM-C levels (.54+.09 vs .47+.07,n=8).
We2conclude that a single bedtime dose of EE as low as 29c2 mcg/m augments the peak GH response to LDT and enhances the discrimination of L-dopa testing for GH reserve. Our results suggest low-dose estrogen rapidly and directly augments GH release, consistent with its enhancing effect on growth. The role of growth hormone (GH) in stunting following headirradiation in rodents and humans is unclear. We have reported no response to GH treatment in the stunted head-irradiated rat. Secretion profile of GH and cell size and number in brain, heart, liver, kidney and gastrocnemius muscle (gastroc) were determined in rats X-irradiated with 600 rads to the head only or sham-irradiated at 2 d of age. Blood was sampled for GH RIA from cannulated undisturbed rats at 15 min intervals for 18 h periods (9 h light and 9 h dark) at 47 to 64 d of age. Irradiated rats were significantly stunted in body weight and tail length. At 20-21d of age they had significantly reduced weight of all organs; decreased brain organlbody ratio (p<0.0005) and total DNA (p<0.0005); increased DNA/organ in all organs, significant in heart (pc0.025) and gastroc (p<0.025); decreased protein/DNA in all organs, significant in brain (p<0.005), heart (p<0.01) and gastroc (p<0.05).
GROWTH HORMONE AND STUNTED GROWTH
Irradiated rats had normal rhythm of GH pulses; reduced numbers of GH values from 200 to 499 ng/ml (p<0.05) and 500 to 999 ng/ml (p<0.005), and reduced area under GH concentration vs time (p<0.025). We conclude that GH secretory rhythm is intact in the head-irradiated rat. Cell size and number results exclude neonatal hypopituitarism and/or undernutrition as causes of the growth stunting. Reduced GH secretion may thus only reflect setting of a putative centrally located growth regulator for a smaller body size.
Studies in vitro, in animals, and in adults have suggested that SM-C. ooeratina at both CNS and ~ituitarv levels. mediates a feedback inh\bitionWof GH secretion. ' To test" this hypothesis in children we studied 11 short (height c 3rd%) boys, ages 7-14 with delayed bone ages and normal GH responses to standard tests. On successive days 2-hour clonidine (5ug/kg,p.o.) and GRF (0.3ug/kg, i.v.) tests were performed in the fasting state. Daily GH (0.1 Ulkg, i.m.) was then given with a repeat clonidine test 20 h after the second dose and a GRF test 20 h after the third.
Results are shown below:
Integrated GH (ng/ml/min) : Clonidine GRF SM-C(U/ml ) Before GH 582584 15-363 0.6350.14 GH x 2d 362+137* 1.46+0.11* GH x 3d 4875 85*
